Does Limited Scleroderma Cause Hypotension?
Limited scleroderma (CREST syndrome) does not typically cause hypotension; instead, it is associated with pulmonary arterial hypertension (PAH) and, rarely, normotensive scleroderma renal crisis where hypotension can occur as a complication rather than a primary feature.
Primary Cardiovascular Manifestation: Pulmonary Arterial Hypertension
Limited cutaneous systemic sclerosis (CREST syndrome) is the main connective tissue disease variant associated with PAH, with a prevalence of 7-12% in large cohorts 1. The pathophysiology involves pulmonary arteriopathy rather than systemic hypotension:
- PAH leads to right ventricular failure, not systemic hypotension
- The therapeutic challenge is actually avoiding systemic hypotension when treating right ventricular failure with vasodilators, inotropes, and diuretics 2
- Echocardiographic screening is recommended for all symptomatic patients with scleroderma spectrum diseases 1
Rare Exception: Normotensive Scleroderma Renal Crisis
While hypertension is the hallmark of typical scleroderma renal crisis, a rare normotensive variant exists where hypotension can develop:
- Normotensive SRC is uncommon and carries a worse prognosis than hypertensive SRC 3
- Hypotension in this context is a complication that makes ACE inhibitor therapy challenging 3
- This represents acute organ failure rather than a chronic manifestation of limited scleroderma
Clinical Pitfalls to Avoid
Do not confuse the absence of hypertension with the presence of hypotension. The scleroderma pulmonary-renal syndrome (distinct from renal crisis) is associated with normal blood pressure, not hypotension 2.
When evaluating a limited scleroderma patient with low blood pressure, consider:
- Right ventricular failure from PAH - check for elevated jugular venous pressure, peripheral edema, and obtain echocardiography
- Pericardial effusion/tamponade - uncommon but can occur 2
- Normotensive renal crisis - look for acute kidney injury, microangiopathic hemolytic anemia, thrombocytopenia 3
- Medication effects - particularly if already on PAH-directed vasodilator therapy
The standard treatment algorithm for PAH in limited scleroderma is the same as for idiopathic PAH 1, but requires careful hemodynamic monitoring to prevent iatrogenic hypotension during vasodilator therapy 2.